Back to Authors

Ayoub, Chadi

Mayo Clinic

Mayo Clinic in Arizona

Citations 3

Prognostic Significance of Prolonged QTc Interval in Patients on Dialysis: A Retrospective Cohort Study
Pham, Hoang Nhat, Ibrahim, R, Giauque, Nathan A., Mahmoud, Ahmed K., Dreher, Luke, Scott, Luis R., Ayoub, Chadi, Arsanjani, Reza, LeMond, Lisa , Singh, Amitoj, Sorajja, Dan , Ayoub, Chadi , Ayoub, Chadi , Pham, Hoang Nhat , Giauque, Nathan Anthony, Mahmoud, Ahmed K , Dreher, Luke , Scott, Luis R. , Arsanjani, Reza , Singh, Amitoj

Journal of Arrhythmia | February 19, 2026 | Volume: 42 | Issue: 1 | Pages: No page available

10.1002/joa3.70299 Get It

ABSTRACT Background Prolonged QT interval is common in end‐stage renal disease (ESRD) on dialysis, but its long‐term cardiovascular (CV) implications remain unclear. Methods Using TriNetX network (2010–2024), we identified adults with ESRD on dialysis and categorized them by QTc status. After 1:1 propensity score matching ( n = 3428/group), outcomes (hazard ratio [HR]) were assessed using Cox regression. Results Prolonged QTc (> 500 ms) was associated with higher risk of all‐cause mortality (HR 1.67; p < 0.001), MACEs (HR 1.40; p < 0.001), cardiac arrest (HR 1.75; p < 0.001), sustained ventricular arrhythmia (HR 1.66; p < 0.001), new‐onset atrial fibrillation (HR 1.12; p = 0.01), and acute myocardial infarction (HR 2.19; p < 0.001). Conclusions In ESRD patients on dialysis, prolonged QT interval was independently associated with adverse CV outcomes and mortality.
Combination therapy with sglt2-inhibitors and tafamidis in transthyretin cardiomyopathy
Forst, B, Ibrahim, R, Chung, K, Pham, H N, Habib, Eiad, Farina, J, Lee, J Z, Ayoub, Chadi, Lee, K, Steidley, Eric, Sorajja, Dan , Rosenthal, J, Arsanjani, R, Forst, Beani, Pham, Hieu , Habib, Eiad , Lee, Justin Z. , Hilal, Talal , Arsanjani, Reza

European Heart Journal | February 4, 2026 | Volume: 46 | Issue: Supplement_1 | Pages: No page available

10.1093/eurheartj/ehaf784.1223 Get It

Abstract Introduction/Background Transthyretin amyloidosis (ATTR) is a debilitating disease that leads to progressive cardiac dysfunction. Tafamidis is the gold standard therapy for ATTR cardiomyopathy. In recent observational studies, sodium-glucose cotransporter-2 inhibitors (SGLT2-Is) have demonstrated cardiovascular benefits in ATTR cardiomyopathy, but their role in ATTR cardiomyopathy as combination therapy with tafamidis remains unclear. Purpose To investigate the impact of combination therapy with tafamidis and SGLT2-Is versus just tafamidis in patients with known ATTR cardiomyopathy. Methods This retrospective cohort study utilized data from the TriNetX multinational database. Patients diagnosed with ATTR cardiomyopathy who received tafamidis were identified and stratified into two cohorts based on SGLT2-I use. Outcomes were assessed over three years, including all-cause mortality, all-cause hospitalizations, acute myocardial infarction (AMI), acute heart failure (HF) hospitalizations, ischemic stroke, atrial fibrillation/flutter, end-stage renal disease (ESRD) or requirement for renal replacement therapy, and ventricular tachycardia. Propensity score matching was used to balance both cohorts based on clinical comorbidities, medication use, and laboratory data. Adjusted odds ratios (OR) were calculated by logistic regression models. Results After propensity score matching, 409 patients were included in each cohort with a follow-up duration of 722 days (SD 320.87) for the SGLT2-I cohort and and 755.90 days (SD 363.26) for the non-SGLT2-I cohort. SGLT2-Is were associated with significantly lower rates of all-cause hospitalizations (41.1% vs. 50.9%; OR 0.67 [p = 0.005]) and AMI (6.6% vs. 13.9%, OR 0.44 [p = 0.001]), which persisted by three years (all-cause hospitalizations: 52.1% vs. 61.4%, OR 0.67 [p = 0.006] and myocardial infarction: 11.2% vs. 18.3%, OR 0.56 [p = 0.004]). No significant differences among the two cohorts were observed for all-cause mortality, acute HF hospitalizations, ischemic stroke, atrial fibrillation/flutter, ventricular tachycardia, or ESRD/need for renal replacement therapy. Conclusions SGLT2-Is, in combination with tafamidis, are associated with decreased all-cause hospitalizations and AMI in ATTR cardiomyopathy. While a mortality benefit was not demonstrated, these results depict the magnitude of clinical benefit derived from combination therapy with tafamidis and SGLT2-Is as opposed to prior observational studies which investigated SGLT2-I single therapy
Percutaneous Left Atrial Appendage Occlusion for Atrial Fibrillation in Cardiac Amyloidosis
Almakadma, Abdul Hakim , Ibrahim, Ramzi, Pham, Hoang Nhat, Habib, Eiad, Mahmoud, Ahmed K., Awad, Kamal, Bhakta, Mayurkumar D. , Yang, Eric H., Masry, Hicham Z. El, Ayoub, Chadi, Arsanjani, Reza, Ayoub, Chadi , Masry, Hicham El , Awad, Kamal , El Masry, Hicham , Ayoub, Chadi , Ibrahim, Ramzi , Pham, Hoang Nhat , Habib, Eiad , Mahmoud, Ahmed K , Awad, Kamal , Yang, Eric H. , Arsanjani, Reza

Journal of Arrhythmia | January 27, 2026 | Volume: 42 | Issue: 1 | Pages: No page available

10.1002/joa3.70274 Get It

ABSTRACT Background Cardiac amyloidosis (CA) is frequently complicated by atrial fibrillation (AF), yet outcomes after left atrial appendage occlusion (LAAO) in this population remain poorly defined. Methods We conducted a retrospective TriNetX study of adults with AF undergoing LAAO, comparing patients with and without CA after 1:1 propensity matching. Outcomes were assessed using Kaplan–Meier analyses and Cox regression. Results Among 532 matched pairs, mortality and major adverse cardiovascular events were similar between groups, whereas major bleeding was higher in CA (HR 1.90). Conclusions LAAO yields comparable ischemic outcomes in CA, though bleeding risk is increased.